FOR IMMEDIATE RELEASE
- New premium, highly personalized international patient program targets individuals traveling from the United States and Canada
- Programs combine physician assessment, regenerative medicine, longevity technologies, diagnostics, and wellness services
- Expansion reflects growing North American interest in destination-based longevity medicine
MIAMI, FL — Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an expanded international patient strategy targeting individuals traveling from the United States and Canada to its Cancun facilities.
The institute is developing comprehensive, premium medical-wellness programs combining physician assessment, regenerative medicine, longevity technologies, diagnostics, and hospitality-oriented patient coordination where appropriate. The programs are intended for international patients seeking a highly personalized, destination-based longevity and regenerative medicine experience.
Cellular Hope Institute described the offering as a premium, highly personalized international patient program, reflecting the individualized nature of physician-directed longevity care rather than a standardized package.
“More patients in the U.S. and Canada are looking for a genuinely comprehensive longevity experience, not just a single procedure,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This program is built around that — physician assessment first, then a program built around the individual patient.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellular Hope Institute
Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), is based in Cancun, Mexico, and provides physician-directed regenerative medicine, longevity, and wellness programs to international patients.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
